Gerard Morton
MB BCh BAO, MRCPI, FRCPC, FFRRCSI
Qualification
- MB BCh BAO, University College Cork, Ireland
- MRCPI, Internal Medicine
- FRCPC, Radiation Oncology
- FFRRCSI, Clinical Oncology
Research Synopsis
- Clinical Trial: Single fraction HDR brachytherapy and hypofractionated external beam radiotherapy for intermediate risk prostate cancer
- Clinical Trial: Use of advanced 3D ultrasound imaging for real-time HDR prostate brachytherapy
- Clinical Trial: Role of short-term androgen deprivation therapy with dose escalated radiotherapy for intermediate risk prostate cancer
- Methods to optimize prostate HDR brachytherapy planning
Recent Publications
Morton G, Loblaw A, Sankreacha R, Deabreu A, Zhang L, Mamedov A, Cheung P, Danjoux C, Szumacher E, Keller B, Thomas G. Single fraction high dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate risk prostate cancer: analysis of short and medium-term toxicity and quality of life. Int J Radiat Oncol Biol Phys 77(3):811-817, 2010.
Morton G, Walker-Dilks C, Baldassare F, D’Souza D, Falkson C, Batchelar D, Gutierrez E, Bak K. Delivery of brachytherapy for cervical cancer: organizational and technical advice to facilitate high quality care. Clin Oncol (R Coll Radiol) 22(7): 605-614, 2010.
Morton G, Loblaw DA, Chung H, Tsang G, Sankreacha R, Deabreu A, Zhang L, Mamedov A, Cheung P, Batchelar D, Danjoux C, Szumacher E. Health related quality of life following single fraction high dose-rate brachytherapy and hypofractionated external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 80(5):1299-1305, 2011.
Holly R, Morton G, Sankreacha R, Law N, Cisecki T, Loblaw DA, Chung HT. Use of cone-beam imaging to correct for catheter displacement in high dose-rate prostate brachytherapy. Brachytherapy 10(4):299-305, 2011.
Lawton CA, Hunt D, Lee WR, Gomella L, Grignon D, Gillin M,Morton G, Pisansky TM, Sandler H. Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 9805). Int J Radiat Oncol Biol Phys 81(1):1-7, 2011.
Morton G, Loblaw A, Cheung P, Szumacher E, Chahal M, Danjoux C, Chung HT, Deabreu A, Mamedov A, Zhang L, Sankreacha R, Vigneault E, Springer C. Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer? Radiother Oncol 100(3):463-467, 2011.
Yamada Y, Rogers L, Demanes DJ, Morton G, Prestidge BR, Pouliot J, Cohen GN, Zaider M, Ghilezan M, Hsu IC. American Brachytherapy Society consensus guidelines for high dose-rate prostate brachytherapy. Brachytherapy 11:20-32, 2012
Appointments
Professor, Department of Radiation Oncology, University of Toronto
Radiation Oncologist, Sunnybrook Odette Cancer Centre
Head of Brachytherapy, Sunnybrook Odette Cancer Centre
Chair, Ontario Association of Radiation Oncologists